Savara Inc Line of Credit, Current
Savara Inc (SVRA) had Line of Credit, Current of $2.00 million as of 2019-12-31, per its 10-K filed 2021-03-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LinesOfCreditCurrent · last filed 2021-03-10
- 2019-12-31: Line of Credit, Current $2.00M.
- 2018-09-30: Line of Credit, Current $3.75M.
- 2018-06-30: Line of Credit, Current $1.88M.
- 2017-03-31: Line of Credit, Current $1.58M.
| Period end | Line of Credit, Current |
|---|---|
| 2019-12-31 | $2.00M 10-K · filed 2021-03-10 |
| 2018-09-30 | $3.75M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $1.88M 10-Q · filed 2018-08-09 |
| 2017-03-31 | $1.58M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $1.55M 10-Q · filed 2017-05-09 |
| 2016-09-30 | $11.59M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $12.51M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $11.45M 10-Q · filed 2016-05-06 |
| 2015-12-31 | $10.99M 10-K · filed 2017-03-06 |
| 2015-09-30 | $1.54M 10-Q · filed 2015-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |